WCN26-4259 TIRZEPATIDE FOR RESISTANT HYPERTENSION IN NON-DIABETIC IGA NEPHROPATHY

Read full text Summarise with VIRAT
Authors: SHAMINI AJIT KUMAR
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Obesity and resistant hypertension accelerate CKD progression through glomerular hyperfiltration and podocyte injury. The FLOW trial demonstrated that semaglutide reduced kidney disease events by 24% in diabetic CKD. However, evidence for GLP-1 receptor agonists in non-diabetic glomerular diseases remains unexplored. We present a case of non-diabetic IgAN with resistant hypertension showing remarkable benefits from tirzepatide

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Blood Pressure and Hypertension Studies

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106223–106223
Publication date
25 March 2026
Language
EN